Entries Tagged as ''

Alfacell Achieves Full Patient Enrollment Milestone

Press Release Source: Alfacell Corporation BLOOMFIELD, N.J., Feb. 27 /PRNewswire-FirstCall/ — Alfacell Corporation (Nasdaq: ACEL – News) today announced that the full enrollment target of 316 patients has been reached for the international, confirmatory Phase IIIb registration trial evaluating ONCONASE® (ranpirnase), the Company’s lead investigational drug candidate, as a treatment for unresectable malignant mesothelioma (UMM).The Company [...]

A brief overview of Mesothelioma cancer

Mesothelioma is a type of cancer that is found usually among men who are advanced in years. This type of cancer is caused from the effects of exposure to asbestos ad as a result affects the membranes of our vital organs such as the heart and lungs. Mesothelioma cancer is not very easy to diagnose [...]

Genetic test for lung cancer patients might help identify chemotherapy needs

According to a report recently published in the New England Journal of Medicine, researchers at Taiwan University have developed a five-gene test that may help show which early-stage lung cancer patients most need chemotherapy. Chemotherapy can be greatly beneficial in slowing or halting the growth of lung cancer in some patients, but have little or [...]